Navigation Links
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting

BELLEVUE, WA, April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego April 12-16, 2008.

Oncothyreon is currently conducting a Phase 1 clinical trial of PX-478 in patients with advanced metastatic cancer and a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer. PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008.

Details regarding these abstracts are as follows:


- Molecular-genetic image guided studies of the antitumor HIF-1alpha

inhibitor PX-478 in combination with radiation

Abstract # 2566, Session: Novel Mechanisms of Drug Action

Presentation: Monday, April 14, 2008, 2:55 p.m. to 3:10 p.m. P.T.

- HIF-1alpha antagonism by PX-478 inhibits progression and spread of

orthotopic human small cell lung cancer and lung adenocarcinoma in


Abstract # 1440, Session: mTOR/Akt/PI3K Inhibitors and

Vascular/Hypoxia Targeting Agents

Poster session: Sunday, April 13, 2008, 1:00 p.m. to

5:00 p.m. P.T.


- Pharmacodynamic evaluation of plasma thioredoxin-1 for patient

enrichment of PX-12 clinical trials

Abstract # 4453, Session: Molecular Signatures and Proteomic


Poster Session: Tuesday, April 15, 2008, 1:00 p.m. to

5:00 p.m. P.T.


- Cellular and in vivo activity of a new PI3K inhibitor PX-866 for

treatment of human glioblastoma

Abstract # 3731, Session: Imaging in Preclinical and Clinical


Poster Session: Tuesday, April 15, 2008, 8:00 a.m. to

12:00 p.m. PT

- Identification of novel synergistic targets RACK-1 and galectin-1 for

rational drug combinations with PI3 Kinase inhibitors using siRNA

synthetic lethality screening

Abstract # 2761, Session: Signal Transduction and Therapeutics

Poster Session: Monday, April 14, 2008, 1:00 p.m. to

5:00 p.m. P.T.

- Phosphatidylinositol 3-kinase stimulates the proliferation of

bronchioalveolar stem cells in mouse models of oncogenic K-ras-

induced lung cancer

Abstract # 5408, Session: Stem Cells

Poster Session: Wednesday, April 16, 2008, 8:00 a.m. to

12:00 p.m. P.T.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for PX-12 and PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12 and PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces effectiveness of shelf registration statement
2. Oncothyreon announces issuance of patent for PX-867
3. Oncothyreon to present at upcoming investment conferences
4. Oncothyreon reports full year and fourth quarter 2007 financial results
5. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
6. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
7. Oncothyreon launches new corporate website
8. Oncothyreon to present at BIO CEO & Investor Conference
9. Oncothyreon highlights corporate and clinical objectives for 2008
10. Biomira announces plan to change name to Oncothyreon
11. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... AWRE ), a leading supplier of biometrics software and services, ... 2015.  --> --> Revenue ... of 33% compared to $6.0 million in the same quarter last ... million, or $0.10 per diluted share, which compared to $2.6 million, ... ago.  --> --> Lower ...
Breaking Biology News(10 mins):